SAN DIEGO, June 13, 2020 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO) today announced that
Janssen Research & Development, LLC (Janssen) presented data
from its Phase III ANDROMEDA (AMY3001) study of subcutaneous (SC)
daratumumab utilizing ENHANZE® in combination with
cyclophosphamide, bortezomib and dexamethasone (CyBorD) for
patients with newly diagnosed light-chain (AL) amyloidosis at the
25th Annual Congress of the European Hematology
Association. Janssen reported that the study met the primary
endpoint of percentage of patients with hematologic complete
response. Additional information can be accessed here.
"We are excited that the subcutaneous formulation of daratumumab
utilizing ENHANZE® has demonstrated positive results in
a potentially new indication addressing an underserved population
with limited treatment options," said Dr. Helen Torley.
About Halozyme
Halozyme is a biopharmaceutical company bringing disruptive
solutions to significantly improve patient experiences and outcomes
for emerging and established therapies. Halozyme advises and
supports its biopharmaceutical partners in key aspects of new drug
development with the goal of improving patients' lives while
helping its partners achieve global commercial success. As the
innovators of the ENHANZE® technology, which can reduce
hours-long treatments to a matter of minutes, Halozyme's
commercially-validated solution has positively impacted more than
400,000 patient lives via four commercialized products across more
than 100 global markets. Halozyme and its world-class partners are
currently advancing multiple therapeutic programs intended to
deliver innovative therapies, with the potential to improve the
lives of patients around the globe. Halozyme's proprietary
recombinant human hyaluronidase enzyme rHuPH20 forms the basis of
the ENHANZE® drug delivery technology and is used to
facilitate the subcutaneous delivery of injected drugs and fluids,
potentially reducing the treatment burden of other drugs to
patients. Halozyme has licensed its ENHANZE® drug
delivery technology to leading pharmaceutical and biotechnology
companies including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly,
Bristol-Myers Squibb, Alexion and argenx. Halozyme derives revenues
from these collaborations in the form of milestones and royalties
as the Company's partners make progress developing and
commercializing their products being developed with
ENHANZE®. Halozyme is headquartered in San Diego. For more information visit
www.halozyme.com.
Halozyme Safe Harbor Statement
In addition to historical information, the statements set forth
above include forward-looking statements including, without
limitation, statements concerning the possible activity, benefits
and attributes of ENHANZE®, the possible method of
action of ENHANZE®, its potential application to aid in
the dispersion and absorption of other injected therapeutic drugs,
and statements concerning certain other potential benefits of
ENHANZE® including facilitating more rapid delivery of
injectable medications through subcutaneous delivery. These
forward-looking statements also include statements regarding the
product development efforts of Halozyme's ENHANZE®
partner. These forward-looking statements involve risks and
uncertainties that could cause actual results to differ materially
from those in the forward-looking statements. The forward-looking
statements are typically, but not always, identified through use of
the words "believe," "enable," "may," "will," "could," "intends,"
"estimate," "anticipate," "plan," "predict," "probable,"
"potential," "possible," "should," "continue," and other words of
similar meaning. Actual results could differ materially from the
expectations contained in forward-looking statements as a result of
several factors, including uncertainties concerning whether
collaborative products are ultimately developed, approved or
commercialized, unexpected expenditures and costs, unexpected
results or delays in development and regulatory review including
any potential delays caused by the current COVID-19 global
pandemic, unexpected regulatory approval requirements, unexpected
adverse events or patient outcomes, and competitive conditions.
These and other factors that may result in differences are
discussed in greater detail in Halozyme's most recent Annual and
Quarterly Reports filed with the Securities and Exchange
Commission. Except as required by law, Halozyme undertakes no duty
to update forward-looking statements to reflect events after the
date of this release
Contact:
Al Kildani
Vice President, Investor Relations and Corporate Communications
858-704-8122
ir@halozyme.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/halozyme-announces-findings-from-janssens-phase-3-andromeda-study-evaluating-subcutaneous-daratumumab-utilizing-enhanze-in-light-chain-amyloidosis-presented-at-european-hematology-association-25th-annual-congress-301076452.html
SOURCE Halozyme Therapeutics, Inc.